Tuesday, September 23, 2025 3:22:37 PM
Cassava Sciences Form 4 Filing Shows CEO Richard Barry Bought 237,941 Shares Of Stock At An Average Price Of $2.25/Share
Benzinga
4:22 PM ET Sep-22-2025
- SEC Filing
One of the directors had made significant investments in Sava stock open market more that once too. In one case he tried to put a “floor” on the drop at much higher prices, I believe in the low teens. How did that work out for him?
Typically its a definite bonus to have insiders buy but in SAVA’s case it always appears on the surface as yo me as “gimmicky” at best.
Anavex’s data will speak for itself and the shareprice will correct accordingly imo.
Recent AVXL News
- Anavex shares collapse after CHMP issues negative signal on Alzheimer’s therapy • IH Market News • 11/14/2025 01:45:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:42:01 PM
- Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease • GlobeNewswire Inc. • 11/14/2025 12:30:00 PM
- Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group • GlobeNewswire Inc. • 10/29/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ • GlobeNewswire Inc. • 10/10/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2025 12:42:50 AM
- Anavex shares climb on upbeat results from schizophrenia trial • IH Market News • 10/02/2025 12:45:17 PM
- Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program • GlobeNewswire Inc. • 10/02/2025 11:35:00 AM
- Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/02/2025 11:30:00 AM
- Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial • GlobeNewswire Inc. • 09/30/2025 12:30:00 PM
- Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial • GlobeNewswire Inc. • 09/09/2025 11:30:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 • GlobeNewswire Inc. • 09/02/2025 11:30:00 AM
- Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine • GlobeNewswire Inc. • 08/26/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 09:30:21 PM
- Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease • GlobeNewswire Inc. • 08/20/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2025 08:08:20 PM
- Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/12/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 • GlobeNewswire Inc. • 08/05/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 07/31/2025 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2025 08:48:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2025 04:15:19 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/14/2025 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
Veri Medtech (VRHI) Files Registration Statement for Proposed Initial Public Offering • VRHI • Nov 17, 2025 8:30 AM
ECGI Appoints AI Platform Architect as CTO to Build Mortgage Tokenization Infrastructure • ECGI • Nov 13, 2025 8:30 AM
Alliance Creative Group (ACGX) Releases 2025 Q3 Quarterly Financial and Disclosure Report • ACGX • Nov 13, 2025 4:40 AM
The Hidden Force Behind the AI Revolution • META • Nov 12, 2025 9:00 AM
The Clean Energy Breakthrough That Could Power the AI Era • MAXXF • Nov 12, 2025 9:00 AM
ECGI Highlights Fintech Expansion Through RezyFi Acquisition and Tokenized Mortgage Platform in Shareholder Letter • ECGI • Nov 11, 2025 8:30 AM
